Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the period ending February 28, 2018. The registrant is a foreign private issuer based in Petach-Tikva, Israel, primarily engaged in the development of drug candidates for metabolic diseases.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to incorporate a press release regarding clinical trial updates and does not contain financial statements.
Material Changes
The material event reported is an update on the Phase II clinical trial of the company's drug candidate, Namodenoson, for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). No financial changes were disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing incorporates by reference the "Forward Looking Statements" section of the attached press release (Exhibit 99.1). The document does not explicitly detail specific guidance, risks, or contingencies within the body text of the Form 6-K itself, deferring to the incorporated press release for such information.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for specific details on the Phase II trial results for Namodenoson.
- Verify the "Forward Looking Statements" incorporated by reference to understand potential risks associated with the clinical trial.
- Consult the company's most recent Form 20-F or quarterly reports for actual financial data, as this filing contains none.